ArticleHemaSphere2025

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.

Maximilian Merz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.